R. Stad

Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review

D. Kendler, F. Cosman, S. Ferrari, 2021, Advances in Therapy.

Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom

E. McCloskey, P. Hadji, E. Hernlund, 2019, Osteoporosis International.

The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids

Stanley B. Cohen, P. Geusens, W. Lems, 2021, Arthritis & rheumatology.

The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study

E. McCloskey, B. Cortet, S. Papapoulos, 2020, Osteoporosis International.

Prevalence of FRAX risk factors and the osteoporosis treatment gap among women ≥ 70 years of age in routine primary care across 8 countries in Europe

E. McCloskey, B. Cortet, S. Papapoulos, 2022, Archives of Osteoporosis.

Prevalence of FRAX risk factors and the osteoporosis treatment gap among women ≥ 70 years of age in routine primary care across 8 countries in Europe

E. McCloskey, B. Cortet, S. Papapoulos, 2022, Archives of Osteoporosis.

Comparability of Osteoporosis Treatment Groups Among Female Medicare Beneficiaries in the United States

L. Spangler, B. Bradbury, J. Curtis, 2023, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage

H. Yan, A. Singer, S. Gandra, 2021, Osteoporosis International.

Cardiovascular Safety in Postmenopausal Women and Men With Osteoporosis Treated With Denosumab and Zoledronic Acid: A Post‐Authorization Safety Study

L. Spangler, R. Hernandez, R. Stad, 2023, JBMR plus.